| abstract |
Improved Aβ protofibril-binding antibody. The present invention relates to amyloid beta peptide (Aβ), more particularly to antibodies that bind to Aβ protofibrils and their use in the medical and/or prophylactic treatment of Alzheimer's disease and other disorders associated with Aβ protein aggregation use. Furthermore, the present invention may relate to the diagnosis of these diseases and monitoring of disease progression through the use of the antibodies of the present invention. Furthermore, the present invention may relate to the veterinary use of the antibodies of the present invention. |